MGI的动态

?? Transformando a Análise Terciária em Oncologia com Illumina Connected Insights-Research! ?? Acompanhar o ritmo das descobertas na oncologia e expandir os menus de testes nunca foi t?o eficiente. Com a plataforma de análise terciária personalizável, Illumina Connected Insights-Research, laboratórios de pesquisa clínica podem facilmente carregar dados e gerar relatórios de pesquisa de maneira ágil e precisa. ?? Personaliza??o e Escalabilidade: Illumina Connected Insights-Research oferece a flexibilidade necessária para se adaptar às crescentes demandas da medicina de precis?o. ?? Eficiência no Fluxo de Trabalho: Desde o upload de dados até a gera??o de relatórios, a plataforma otimiza cada etapa do processo, permitindo que os laboratórios mantenham o foco na inova??o. ?? Avan?os em Medicina de Precis?o: Esteja à frente das novidades e expanda suas capacidades de teste com uma solu??o que cresce junto com as necessidades do seu laboratório. Junte-se a nós na revolu??o da análise terciária em oncologia e vá além com a Illumina! #Oncologia #MedicinaDePrecis?o #Inova??o #PesquisaClínica #Illumina #ConnectedInsights #AnáliseTerciária https://lnkd.in/eWjDUvUe

Exciting industry News ??? Bosch ?? ?Randox to Invest €150M Into New PCR Tests for Vivalytic POC Platform. Bosch Healthcare Solutions and Randox are now joining forces in an attempt to accelerate the development and market launch of new tests and to make distribution channels more efficient. The partnership is set to run for more than ten years. With Vivalytic, the two companies aim to achieve sales in the medium nine-figure range by 2030. One focus of the development partnership with Randox is the implementation of a highly sensitive multiplex test for sepsis on the Vivalytic analysis platform. Bosch Healthcare Solutions and Randox already collaborated during the Covid-19 pandemic. In spring 2020, Bosch launched one of the world’s first fully automated PCR tests for the SARS-CoV-2 coronavirus. Together with Randox, the rapid test for use in doctor’s offices, nursing homes, testing stations, and hospitals was made ready for the Vivalytic analysis device within the space of just a few weeks. An interesting read, I would recommend you check this article out. #IVD #Diagnostics #POCT #Pointofcare #PCR https://lnkd.in/e-Nh3XXi

Dinesh Chauhan, CEO, CORE Diagnostics in Conversation with Bruno Occhipinti, CEO, Qritive; emphasizes oncology as a critical focus at CORE Diagnostics, where quick, accurate pathology results can significantly impact cancer treatment timelines. Since cancer patients require urgent intervention, faster report delivery enables doctors to initiate treatments sooner, potentially improving patient outcomes. He envisions AI and digitization helping to streamline the diagnostic process, enabling pathologists to manage cases more effectively and providing oncologists with integrated reports that combine pathology, radiology, and other diagnostic data for comprehensive cancer care. ?? Innovation at CORE Diagnostics: Dedicated to pioneering advancements for efficient, accessible, and precise diagnostics in India ?? Oncology Focus: Timely pathology results crucial for cancer treatment; quicker reports support better patient outcomes. ?? Integrated Diagnostics: CORE envisions AI-driven reporting that merges pathology, radiology, and diagnostic data for comprehensive cancer care. ?? AI & Digitization Impact: Reducing workload, boosting accuracy, and enabling remote diagnostics. ?? Challenges in Indian Pathology: Limited pathologists and high demand call for faster turnaround times. Dinesh Chauhan Bruno Occhipinti Shivani Sharma Sagar Samrat Mohanty https://lnkd.in/gcwTWFJK #ArtificialIntelligence #Digitization #IndianPathology #Oncopathology #Pathology #Diagnostics #COREDiagnostics #Qritive #AIinOncology #Digitalpathology

Exactis Innovation: Reflecting on a Decade of Impact Today, I share a deeply bittersweet update about Exactis Innovation. After ten transformative years as a cancer research network funded by the Business-Led National Centres of Excellence (BL-NCE) Program, we must announce that Exactis will close its doors early in the new year. Exactis began with a bold vision: to provide patients with access to molecular testing, opening the door to trials for targeted therapies when such testing was not yet standard. Over the years, we adapted, evolved, and ultimately became a trusted source of decision-grade real-world evidence for cancer care. What we’ve accomplished together: -Built a network of 16 cancer centers across six provinces and curated a databank of over 11,000 patients. -Partnered with Canada’s Drug Agency (CDA) to inform real-world oncology market access decisions. -Showcased the immense potential of a pan-Canadian collaboration in leveraging patient data for the greater good. These milestones were only possible because of the unwavering support of so many. To the patients who entrusted us with their data, the coordinators and PIs at our sites, the Exactis team, our Board, and our partners—thank you. Your commitment made our mission not just possible, but meaningful. As we face the financial realities that have brought us to this decision, we remain committed to ensuring our databank continues to serve research and improve outcomes in cancer care. We will share details about its availability for future use as soon as possible. Exactis has proven that Canada's patients, researchers, and institutions can unite to break down barriers and drive innovation. My hope is that this legacy inspires others to dream big and create the next chapter in cancer research. To those ready to envision an "Exactis 2.0," I wish you courage and success. Let’s continue striving for a future where real-world data empowers breakthroughs and transforms lives. With gratitude and hope, Kostas Trakas, PhD CEO, Exactis Innovation

?? Eficiência e produtividade! ?? Qualidade e precis?o! Saiba mais em: ?? https://lnkd.in/e5hTtQ8W #sysmex?#sysmexway?#hematologia?#tecnologia?#inova??o?#diagnóstico?#produtividade?#inteligência?#análisesclínicas

Excelente publica??o mesmo!!! E um tópico espinhoso dentro de um tema complexo. Leitura essencial.

Clinical teams today often don’t have the luxury of investing significant time in learning how to optimize a new technology solution to meet their practice needs. Collaboration between manufacturers, clinical subject-matter experts and clinicians can help to achieve the goal of leveraging new technologies to expand patient access to better treatment options and outcomes. Learn more about how we collaborate to help drive technology adoption and improved utilization. https://bit.ly/46ss8CF

Oncologia com inova??o!

GE Healthcare has bold plans to increase revenues by adding more than 100 AI-enabled devices in the next three years.